Latest News & Features
Biotechnology
UPC overturns previous decision barring NanoString from selling CosMx products in 17 European countries | Court did not stay proceedings on account of NanoString’s Chapter 11 filing. 27 February 2024
Biotechnology
DePuy Synthes tries to overturn a ruling over knee replacement device | Challenges the court's decision, including ownership disputes, interpretation of critical terms, and the granting of a permanent injunction. 27 February 2024
Medtech
Australia-based spinal orthotics device company files suit against ChiroLux | Alleges infringement of one of its chiropractic products aimed at relieving neck pain. 22 February 2024
Biotechnology
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs. 22 February 2024
Unified Patent Court
International membership organisation launches platform enabling access to UPC cases and statistics | Tool aims to provide transparency amidst concerns and latest decision requiring legal representation to request access to court documents | Life sciences cases take up two-thirds of UPC cases. 20 February 2024
Big Pharma
Board determines that Nevro added subject matter to patent through amendment | Medtronic and Boston Scientific have successfully overturned 2019 decision rejecting opposition. 20 February 2024
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter. 20 February 2024
Generics
While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos. 18 February 2024
Big Pharma
Judge says UK courts should depart from a European precedent following Brexit | MSD counsel says appeal had been granted due to courts' “ flip-flopping” on the precedent(s) set by the landmark cases Neurim and Santen. 15 February 2024
Big Pharma
US pharma firm has not admitted liability as part of agreement with Lipitor buyers following a long-running dispute over a cholesterol drug | Litigation against Sun Pharma’s Ranbaxy will continue. 15 February 2024